Regeneron enters neurology field as FDA approves siRNA for myasthenia gravis
Regeneron’s siRNA therapy cemdisiran has become the second new drug approved by the FDA for myasthenia gravis inside of a week. Now named Livsayis, the therapy was approved by the FDA for ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.